Mercedes Davalos-Salas
Overview
Explore the profile of Mercedes Davalos-Salas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ng I, Luk I, Nightingale R, Reehorst C, Davalos-Salas M, Jenkins L, et al.
Am J Physiol Gastrointest Liver Physiol
. 2023 Oct;
325(6):G508-G517.
PMID: 37788331
High-fat (HF) diets (HFDs) and inflammation are risk factors for colon cancer; however, the underlying mechanisms remain to be fully elucidated. The transcriptional corepressor HDAC3 has recently emerged as a...
2.
Chueh A, Tse J, Dickinson M, Ioannidis P, Jenkins L, Togel L, et al.
Clin Cancer Res
. 2023 Sep;
29(18):3826.
PMID: 37712140
No abstract available.
3.
Togel L, Nightingale R, Wu R, Chueh A, Al-Obaidi S, Luk I, et al.
Sci Rep
. 2023 Feb;
13(1):2422.
PMID: 36765160
No abstract available.
4.
Yap Y, McLeod K, McKenzie C, Gavin P, Davalos-Salas M, Richards J, et al.
Clin Transl Immunology
. 2021 Jan;
10(1):e1233.
PMID: 33489123
Objectives: During gastrointestinal infection, dysbiosis can result in decreased production of microbially derived short-chain fatty acids (SCFAs). In response to the presence of intestinal pathogens, we examined whether an engineered...
5.
Davalos-Salas M, Mariadason J, Watt M, Montgomery M
Biochem Pharmacol
. 2020 Jun;
178:114091.
PMID: 32535104
The incidence of obesity and type 2 diabetes continues to rise across the globe necessitating the need to identify new therapeutic approaches to manage these diseases. In this review, we...
6.
Davalos-Salas M, Montgomery M, Reehorst C, Nightingale R, Ng I, Anderton H, et al.
Nat Commun
. 2019 Nov;
10(1):5291.
PMID: 31757939
Histone deacetylase 3 (Hdac3) regulates the expression of lipid metabolism genes in multiple tissues, however its role in regulating lipid metabolism in the intestinal epithelium is unknown. Here we demonstrate...
7.
Meka A, Jenkins L, Davalos-Salas M, Pujara N, Wong K, Kumeria T, et al.
Pharmaceutics
. 2018 Dec;
10(4).
PMID: 30562958
Suberoylanilide hydroxamic acid (SAHA) or vorinostat (VOR) is a potent inhibitor of class I histone deacetylases (HDACs) that is approved for the treatment of cutaneous T-cell lymphoma. However, it has...
8.
Eissmann M, Dijkstra C, Wouters M, Baloyan D, Mouradov D, Nguyen P, et al.
Cancer Immunol Res
. 2018 Feb;
6(4):409-421.
PMID: 29463593
Interleukin 33 (IL33) is an inflammatory cytokine released during necrotic cell death. The epithelium and stroma of the intestine express large amounts of IL33 and its receptor St2. IL33 is...
9.
Togel L, Nightingale R, Wu R, Chueh A, Al-Obaidi S, Luk I, et al.
Sci Rep
. 2018 Jan;
8(1):1767.
PMID: 29379130
The ERK signalling pathway regulates key cell fate decisions in the intestinal epithelium and is frequently dysregulated in colorectal cancers (CRCs). Variations in the dynamics of ERK activation can induce...
10.
Chueh A, Tse J, Dickinson M, Ioannidis P, Jenkins L, Togel L, et al.
Clin Cancer Res
. 2017 Jun;
23(18):5573-5584.
PMID: 28611196
Histone deacetylase inhibitors (HDACi) are epigenome-targeting small molecules approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma. They have also demonstrated clinical activity in acute myelogenous leukemia, non-small...